Arthritis hope.TREATMENT of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. may be turned on its head after a landmark trial, it was revealed. One expert said the findings, indicating the use of an advanced antibody drug at an early stage of the disease, could lead to a "paradigm shift" in therapy. Almost 500,000 people in the UK are affected by rheumatoid arthritis (RA), which occurs when the body's immune system attacks its own joints. Around 40% of sufferers are forced to stop work during the first five years of their illness. Under current guidelines, it is only after patients have failed to respond to an anti-TNF that they qualify for the antibody drug rituximab, marketed as MabThera. Originally developed to treat leukaemia, the injected drug targets specialised white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies which play a key role in the immune response behind RA. The new trial findings show that administering rituximab early, alongside methotrexate methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. , can virtually stop the disease in its tracks.. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion